צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: Matinas BioPharma (MTNB)

Matinas BioPharma develops innovative drug delivery systems via its LNC platform, attracting patients with severe infections to MAT2203 trials due to low toxicity. The annual sales growth rate over a 12-month period demonstrates revenue dynamics, where the value of 0.00 characterizes this level. The development strategy relies on the expansion of LNC technologies and the broadening of B2B licensing to capture the global pharmaceutical market.
פילוחי נתונים אנליטיים מרוכזים עבור Matinas BioPharma (MTNB)

Revenue dynamics for Matinas BioPharma (MTNB), which is based on proprietary drug delivery technology, are assessed by comparing total revenues over the last 12 months with the same period last year to identify expansion rates. An analysis of the trailing twelve months (TTM) growth in operating sales revenue determines whether inertial demand for the treatment of metabolic diseases is converting into sustainable financial growth without excessive costs.